Squarepoint
RXII

Squarepoint’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Squarepoint’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-11,000
Closed -$16K – 1684
2015
Q4 		$16K Buy
+11,000
New +$16K ﹤0.01% 1210

Other funds holding RXII

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Squarepoint's RXII Position: Q1 2016 in Review

Squarepoint sold out of GALENA BIOPHARMA INC COM (RXII) in Q1 2016, closing a stake of 11,000 shares — an estimated $16K sold.

Squarepoint first reported a position in RXII in Q4 2015 and held it in 1 quarter. The position peaked at $16K in Q4 2015. 71 funds tracked by Wall St. Rank hold RXII as of Q1 2016.

  • Squarepoint reported no remaining GALENA BIOPHARMA INC COM position as of Q1 2016 after selling out during the quarter.
  • Squarepoint sold 11,000 GALENA BIOPHARMA INC COM shares in Q1 2016, an estimated $16K.
  • Squarepoint first reported a position in GALENA BIOPHARMA INC COM in Q4 2015 and held it in 1 quarter.
  • Squarepoint's GALENA BIOPHARMA INC COM position peaked at $16K in Q4 2015.
  • 71 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q1 2016.

Based on Squarepoint's 13F filing for Q1 2016, filed 16 May 2016.